#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bile acid synthesis disorder Hairy cell leukaemia IgA nephropathy Acute graft versus host disease Oesophageal carcinoma Bone marrow disorder Colitis ulcerative Angelman's syndrome Brain abscess Immune-mediated myasthenia gravis Ischaemic stroke Warm autoimmune haemolytic anaemia Candida infection Alport's syndrome Chronic hepatitis B More trials…

    Learn about Rare Diseases

    Pituitary-dependent Cushing’s syndrome – Treatment Congenital nephrogenic diabetes insipidus – Diagnostics Toxic epidermal necrolysis Medulloblastoma – Life with Disease Aicardi-Goutieres syndrome – Diagnostics Von Willebrand’s disease Bronchiolitis obliterans syndrome – Diagnostics Rhabdomyosarcoma – Trials in Disease Optic glioma – Life with Disease Pulmonary fibrosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tiapride Blinatumomab Prednisone Fidanacogene Elaparvovec Calcium Oxybate Mk-2060 Cobamamide Maridebart Cafraglutide Vibegron Codeine Phosphate Hemihydrate ORX750 Aclidinium Bromide Darunavir Mr0005 Dorzolamide Hydrochloride Ladarixin Ly3556050 Olopatadine Captopril Desogestrel More therapies…

    Learn about Your Condition

    Anaplastic thyroid cancer Mantle cell lymphoma recurrent Breast cancer stage IV Breast cancer in situ Gender dysphoria Nephrogenic anaemia Meningioma malignant Chronic spontaneous urticaria Gingival bleeding Inflammation Oral lichen planus Cholestatic pruritus Polycythaemia vera Fracture infection Cerebral amyloid angiopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • Study of Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone for Treating Multiple Myeloma Patients with Extramedullary Disease

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Cyclophosphamide
    • Daratumumab
    Greece Italy

  • Study on the Safety and Tolerability of OsteoDex for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Osteodex
    Sweden

  • Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Isatuximab
    • Carfilzomib
    • Lenalidomide
    Germany

  • Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Precursor B-lymphoblastic lymphoma
    • Burkitt’s lymphoma
    • Marginal zone lymphoma
    Investigated Drugs:
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    Germany

  • Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Methylprednisolone
    • Ponatinib
    • Methotrexate
    Italy

  • Study on Masitinib for Patients with Severe Mast Cell Activation Syndrome Unresponsive to Treatment

    Not recruiting

    2 1
    Investigated Diseases:
    • Mast cell activation syndrome
    Investigated Drugs:
    • Masitinib
    France
Previous Page
1 … 57 58 59 60 61 … 89
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!